Michael Celano Email & Phone Number

Bala Cynwyd, PA, US

Publicly-held clinical-stage biotechnology company (NASDAQ: LRMR) focused on developing treatments for complex rare diseases.

Bethlehem, Pennsylvania, US

Industry leader of oral fluid diagnostic and collection technologies.

Chief Operating Officer (2018-2019); Chief Financial Officer (2016-2017)): Specialty pharmaceutical company with a high performing revenue generating contract development and manufacturing (CDMO) division.

Private- equity funded consumer products branded heath, wellness and self-care company. Sold in 2016 to Patterson Medical (Madison Dearborn).

Horsham, Pennsylvania, US

Private equity-funded clinical laboratory services company with annualized revenue growth run rate of over 25%. Sold in 2017 to ACM Global Laboratories

Medical device company ($90 million in annual revenues) focused on regenerative medicine utilizing its proprietary collagen and polymer technology. Sold to Royal DSM (DSM) for $38.50 per share, an all time high. During three-year tenure, Kensey Nash transformed itself from a contract manufacturer to a profitable regenerative medicine business. As co-leader.

London, GB

Led business development activities in key U.S. markets, focused on product/clinical trial, D&O and enterprise risk management.

Venture-funded life sciences company. Grew from a 20-person start-up with a $35 million valuation to being sold in 2007 to Pfizer in a cash transaction totaling approximately $200 million.

Starting with Arthur Andersen in 1980, spent early career servicing venture-funded, public technology-based companies. Focused on life sciences industry as it grew in the late 1980s, eventually becoming Partner-in-Charge of Andersen’s Life Sciences Practice in the Mid-Atlantic Region in 1994. From 2000 to 2002, co-chaired Andersen’s U.S. Life Sciences.